For Clinicians | Doxycycline Uses

Lyme Prophylaxis, Malaria Prevention, Acne, and the Doxy-PEP Debate

By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, Jase
Medically reviewed and edited by Kristen Carpenter, PA-C

We’re continuing our series on the antibiotics we see most often come up in medical preparation conversations, one drug at a time. This week it is ….drum roll please…..doxycycline’s turn.

Doxycycline is basically the Swiss Army knife of antibiotics, except instead of a bottle opener and tiny scissors, you get malaria prevention and clearer skin. Want stellar proof? It works on Lyme disease protocol, a malaria prevention plan, an acne prescription, and now a post-exposure STI regimen. Doxycycline really does treat five unrelated problems. It isn’t that the drug just has killer marketing (although, it totally does that). It’s pharmacology: one mechanism, several targets, and, as it turns out, a guideline landscape that doesn’t fully agree on how to use it.

Take the tick bite question. The Infectious Diseases Society of America, the American Academy of Neurology, and the American College of Rheumatology all endorse a single 200 mg dose within 72 hours of a high-risk bite¹. The International Lyme and Associated Diseases Society doesn’t². Same drug and window, yet different answer depending on which guideline you’re using.

What is doxycycline used for?

More than you’d expect from one antibiotic. Doxycycline treats Lyme disease, prevents malaria, clears chlamydia, controls acne and rosacea, and, as of a 2024 CDC update³, prevents certain bacterial STIs after exposure in specific patients. 

That’s not doxycycline being a jack-of-all-trades in the vague sense. It comes down to mechanism. Doxycycline blocks protein synthesis in bacteria, the same core action tetracyclines have always had. It also disrupts a structure inside the malaria parasite called the apicoplast, a leftover organelle the parasite can’t survive without.

Quick reference: doxycycline by indication

Treatment: Lyme disease (a 10-day course performs as well as longer regimens⁴), rickettsial infections, chlamydia, and acne or rosacea.

Prevention: a single 200 mg dose within 72 hours of a high-risk tick bite, or daily dosing started before travel to a malaria-endemic area⁵.

Adjunct: reduces gum-pocket depth after periodontal treatment⁶.

Anthrax exposure: 100 mg twice daily for 60 days⁷., the CDC’s long-standing post-exposure regimen following high-risk Bacillus anthracis exposure. This one’s been on the Strategic National Stockpile for over two decades, not a new addition.

Emerging and debated: a single post-exposure dose to reduce the risk of certain bacterial STIs. That one’s newest, and it’s not settled, so it gets its own section next.

Five categories, one drug. Four of which are on well-worn clinical ground.

Where this fits into appropriate medical preparation

Three of these five uses are built for a standby kit: the single tick-bite dose, prescribed before symptoms show up; the pre-travel malaria regimen, started before a patient ever sets foot somewhere with risk; and doxycycline kept on hand ahead of a possible anthrax exposure. These work only because they’re prescribed ahead of need, not after.

That’s what we mean by appropriate medical preparation: a bounded, clinician-controlled step for conditions where the evidence is strong and the timing is predictable well in advance.

Acne, chlamydia treatment, and Doxy-PEP don’t fit that same frame. Each is answering a different clinical question, on a different timeline. None of this is a replacement for primary care. It’s the same clinical standard we’d apply at the time of symptoms, just applied earlier, for the narrow slice of doxycycline’s uses where earlier actually helps.

The bottom line

Doxycycline’s breadth isn’t hype or overuse. It has a great mechanism that allows one antibiotic to serve in several clinical roles since it blocks protein synthesis in bacteria and disrupts a different structure entirely in the malaria parasite. Most of that list is settled, well-worn clinical ground. Doxy-PEP isn’t. CDC’s 2024 guidance applies it to a defined population, adults with a bacterial STI diagnosis in the past 12 months, not sexually active adults broadly³. That population has already been redrawn once: WHO issued its own endorsement in 2026, broadly aligning with CDC, while Europe’s ECDC held back, citing resistance concerns over a population-level rollout⁸ ⁹. 

The uses that actually belong in a standby kit, prescribed ahead of need, are the tick-bite dose, pre-travel malaria regimen, and anthrax exposure backup. That’s the appropriate medical preparation slice of this list, and it’s the piece Jase is built around.

Sources

1. IDSA/AAN/ACR 2020 Lyme guideline, single 200 mg dose within 72 hours of a high-risk tick bite. Infectious Diseases Society of America. idsociety.org/practice-guideline/lyme-disease
2. ILADS treatment guidelines (the dissenting position). ilads.org/patient-care/ilads-treatment-guidelines
3. CDC Clinical Guidelines on Doxycycline Postexposure Prophylaxis, MMWR 2024. Confirms 200 mg within 72 hours, population is MSM and transgender women with a bacterial STI in the past 12 months. cdc.gov/mmwr/volumes/73/rr/rr7302a1.htm
4. Shorter versus longer antimicrobial therapy for early Lyme disease, systematic review and meta-analysis, confirming no significant difference between ≤10-day and longer courses. sciencedirect.com/science/article/abs/pii/S0732889324000440
5. CDC Yellow Book, Malaria chapter, chemoprophylaxis dosing and timing. cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/malaria.html
6. Subantimicrobial-dose doxycycline (Periostat), FDA-approved 1998 as adjunct to scaling and root planing, reduces pocket depth. ncbi.nlm.nih.gov/pmc/articles/PMC6473443
7. CDC Anthrax Doxycycline Emergency Use Instructions, 100 mg twice daily for 60 days post-exposure. stacks.cdc.gov/view/cdc/56837/cdc_56837_DS1.pdf
8. WHO news release, first recommendation on doxycycline PEP, May 28, 2026. who.int/news/item/28-05-2026-who-issues-first-recommendation-on-doxycycline-post-exposure-prophylaxis
9. ECDC guidance on doxycycline for STI prevention, January 2026, recommends against population-level rollout. ecdc.europa.eu/en/news-events/ecdc-issues-guidance-doxycycline-sti-prevention

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

Do You Actually Need Antibiotics?

By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, Jase
Medically reviewed by Kristen Carpenter, PA-C — Clinical Advisory Board Member

Three patients, same complaint. One had a rough day after a backyard barbecue and is already turning the corner. One picked up whatever’s going around at daycare and brought it home to the whole family. One has lived with vague stomach discomfort for years. Ask any of the three if they have “a stomach infection” and they’d probably all say yes.

Only one of them actually does, in the literal sense. And not commonly tested for.

Food poisoning and the stomach flu get lumped in with real stomach infections constantly. Food poisoning and norovirus are usually done doing their damage by the time a patient’s in front of you, so there’s nothing left for an antibiotic to fix. There’s one specific presentation where reaching for antibiotics anyway doesn’t just fail to help, it can actively hurt the patient. And H. pylori sits underneath all of it: a real bacterial infection that can live in the stomach for years without a single symptom, then show up as heartburn nobody connects to the actual cause, and it’s the one of these three that almost always needs a real antibiotic course once someone thinks to look for it.

Getting this right changes what happens at the pharmacy counter and in urgent care. Here’s where the actual lines are for these top 3 ‘stomach bug’ presentations.

Do You Need Antibiotics for Food Poisoning or the Stomach Flu?

Almost never.
The reason is different for each.

Norovirus, the actual “stomach flu,” is viral. There’s no antibiotic target. Fluids and time are the entire treatment, and most people are through the worst of it in one to three days.

Food poisoning is where people expect a prescription and usually don’t need one. Most cases, Salmonella, Campylobacter, the toxin-producing bugs from undercooked meat or food left out too long, are self-limited in a healthy adult. IDSA’s own 2017 guidelines back this up directly: for uncomplicated Salmonella and Campylobacter in immunocompetent patients, the recommendation is supportive care, not antimicrobial therapy.¹ Antibiotics don’t reliably shorten the illness in these cases, and for Salmonella specifically, treating an otherwise uncomplicated infection can prolong how long someone keeps shedding the bacteria afterward.

There is only one big exception and that’s important for you to know. 

Bloody Diarrhea and Fever: Why Reaching for Antibiotics Can Backfire

This is the one every instinct in the room gets wrong, patient and clinician alike. Bloody diarrhea with fever looks like exactly the presentation that needs an antibiotic fast. It’s also the presentation where giving one, before you know what you’re treating, can make things worse.

The organism to worry about is Shiga toxin-producing E. coli, STEC, the kind behind most O157:H7 outbreaks. Killing the bacteria with an antibiotic can cause it to release more Shiga toxin as it dies, and that toxin is what drives hemolytic uremic syndrome, the kidney injury that’s the real danger here, especially in kids. CDC is direct about this: clinicians treating a patient whose presentation suggests STEC should know that giving an antimicrobial may raise the risk of HUS rather than lower it.² IDSA’s own guidelines back this with a strong recommendation: empiric antibiotics for bloody diarrhea, given before results are back, are not recommended in immunocompetent children or adults.³ For STEC confirmed to produce Shiga toxin 2, or when the toxin type isn’t yet known, IDSA goes further and says antimicrobial therapy should be avoided outright.⁴

The same logic applies to anti-diarrheal medications like loperamide. Slowing the gut down means the toxin sits in contact with the colon longer, and that’s also linked to higher HUS risk. The instinct to reach for Imodium while waiting on results is worth stopping while you’re at it.

This isn’t a blanket rule against ever treating bacterial diarrhea, and the mechanism explains why switching drugs isn’t a clever workaround: fluoroquinolones and trimethoprim-sulfamethoxazole are both potent triggers of the same bacterial stress response that ramps up Shiga toxin production. The largest look at real-world outcomes hasn’t found any antibiotic class that’s actually safer than the others. The safe default while you’re waiting on a stool culture and Shiga toxin testing stays the same: don’t treat empirically, and don’t reach for anti-motility agents, until you know what you’re dealing with.

1. Pylori: The Infection That Can Sit for Years Before Anyone Tests for It

This is the one that doesn’t announce itself. H. pylori can live in the stomach lining for years without a single symptom, then surface as heartburn, bloating, or vague upper-abdominal discomfort that gets blamed on stress, coffee, diet, or just getting older. By the time someone brings it up, they’ve often been living with it for a decade.

It won’t show up on a routine stool culture. Culture works by growing an organism, and H. pylori isn’t detected that way.⁵ Finding it takes a test built for it specifically: a urea breath test, which picks up the byproduct of the bacteria’s own urease enzyme, or a stool antigen test, which looks for H. pylori antigen directly. Either has to be ordered by name; neither is part of a standard workup.

The stakes here go past symptom relief. WHO’s cancer research arm classified H. pylori as a human carcinogen back in 1994, and the evidence has only held up since: it’s a major driver of non-cardia gastric adenocarcinoma, and nearly every patient with gastric MALT lymphoma tests positive for it.⁶ That’s the actual argument for testing someone whose “just stress” stomach discomfort has gone on for years, not just comfort, an infection tied to cancer risk that’s fully treatable once it’s found.

And when it’s confirmed, treatment isn’t a guess. Fourteen days now beats the older 7 to 10 day courses, eradication rates run meaningfully higher.⁷ Which drugs matter too: clarithromycin-based triple therapy only holds up where local resistance is low and the patient hasn’t had a macrolide recently, and bismuth-based quadruple therapy is the safer default when resistance status is unknown.⁸ This is a real regimen decision, not a reflexive prescription.

Quick Reference: Which One, Which Answer

Norovirus (viral “stomach flu”): No test needed in typical cases. No antibiotics, there’s no target. Fluids and time, usually resolved in 1 to 3 days.

Uncomplicated food poisoning (Salmonella, Campylobacter, toxin-mediated): Stool culture only if severe, prolonged, or high-risk. Antibiotics not recommended for uncomplicated cases in immunocompetent patients. Supportive care is the treatment.

Bloody diarrhea with fever (possible STEC): Stool culture plus Shiga toxin testing, ordered specifically, before treating. Avoid empiric antibiotics and avoid anti-motility agents like loperamide until results are back. Avoid antimicrobials outright if Shiga toxin 2 is confirmed or the toxin type is unknown.

1. pylori: Urea breath test or stool antigen test, ordered by name, not caught by routine stool culture. When confirmed, a real 14-day antibiotic course, bismuth quadruple therapy if resistance status is unknown, clarithromycin triple therapy only where local resistance is low.

What to Tell Your Patient

Most stomach bugs, the kind that hit hard and fast after a bad meal or a bug going around, don’t need antibiotics at all. Fluids, rest, and a few days usually settle it.

One exception: if diarrhea turns bloody and comes with fever, that’s a reason to call rather than push for an antibiotic. In some cases, antibiotics can make it worse instead of better, and that’s not an intuitive thing for a patient to already know.

The other stomach conversation to bring up: years of stomach discomfort chalked up to stress, coffee, or getting older is worth a specific test, not a shrug or an Rx for omeprazole. If it turns out to be H. pylori, it’s treatable.

The Bottom Line

Three complaints, one label, three different right answers. Most stomach bugs, viral or bacterial, resolve on their own and never need an antibiotic. The one case where reaching for one anyway can genuinely hurt a patient is bloody diarrhea with fever: test for Shiga toxin before treating, and skip the anti-motility agents too until you know what you’re dealing with. And the condition patients have been living with for years without a name, chronic dyspepsia blamed on stress or diet, deserves a specific test rather than another round of empiric PPI. If it’s H. pylori, a real 14-day course clears it.

Getting the label right is the whole job here. Getting it wrong either denies someone a cure they’ve needed for a decade, or pushes a treatment that makes a dangerous case worse.

Sources

1. IDSA, 2017 Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea: for uncomplicated Salmonella and Campylobacter infection in immunocompetent patients, the recommendation is supportive care rather than antimicrobial therapy, and treating uncomplicated Salmonella can prolong the carriage state: https://pmc.ncbi.nlm.nih.gov/articles/PMC5848254/
2. CDC, Information for Clinicians: E. coli Infection: administering antimicrobial agents to a patient whose presentation suggests STEC may increase the risk of hemolytic uremic syndrome; anti-motility agents in STEC infection may increase the risk of toxic megacolon, HUS, and neurologic complications: https://www.cdc.gov/ecoli/hcp/guidance/index.html
3. IDSA, 2017 Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea, Recommendation 30: empiric antimicrobial therapy for bloody diarrhea while awaiting diagnostic results is not recommended in immunocompetent children and adults (strong recommendation, low-quality evidence): https://pmc.ncbi.nlm.nih.gov/articles/PMC5848254/
4. IDSA, 2017 Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea, Recommendation 35: antimicrobial therapy for infections attributed to STEC O157 and other STEC producing Shiga toxin 2, or when the toxin type is unknown, should be avoided (strong recommendation, moderate-quality evidence): https://pmc.ncbi.nlm.nih.gov/articles/PMC5848254/
5. Merck Manual, Helicobacter pylori Infection: bacterial culture has limited use for H. pylori because of the organism’s fastidious nature; urea breath testing and stool antigen testing are preferred for initial diagnosis: https://www.merckmanuals.com/professional/gastrointestinal-disorders/gastritis-and-peptic-ulcer-disease/helicobacter-pylori-infection
6. National Cancer Institute, H. Pylori and Cancer fact sheet: the World Health Organization’s International Agency for Research on Cancer classified H. pylori as a human carcinogen in 1994; it increases the risk of non-cardia gastric adenocarcinoma, and nearly all patients with gastric MALT lymphoma show signs of infection: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/h-pylori-fact-sheet
7. Cochrane, Ideal length of treatment for Helicobacter pylori eradication (Review CD008337): across 45 studies, extending PPI-based triple therapy from 7 to 14 days raised the eradication rate from 72.9% to 81.9% (NNT 11): https://www.cochrane.org/CD008337/UPPERGI_ideal-length-of-treatment-for-helicobacter-pylori-h.-pylori-eradication
8. American Academy of Family Physicians, H. pylori Infection: ACG Updates Treatment Recommendations: clarithromycin should be avoided where local resistance exceeds 15%; bismuth quadruple therapy should be strongly considered first-line where clarithromycin resistance is high or with any prior macrolide exposure; no regimen achieves a 100% cure rate: https://www.aafp.org/pubs/afp/issues/2018/0115/p135.html